NO761407L - - Google Patents
Info
- Publication number
- NO761407L NO761407L NO761407A NO761407A NO761407L NO 761407 L NO761407 L NO 761407L NO 761407 A NO761407 A NO 761407A NO 761407 A NO761407 A NO 761407A NO 761407 L NO761407 L NO 761407L
- Authority
- NO
- Norway
- Prior art keywords
- indolyl
- group
- denotes
- compounds
- ketone
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 230000002295 serotoninergic effect Effects 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000003277 amino group Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 239000002547 new drug Substances 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- -1 nitro, hydroxy Chemical group 0.000 description 18
- 239000000243 solution Substances 0.000 description 16
- 239000000155 melt Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- LDCYZAJDBXYCGN-UHFFFAOYSA-N 5-hydroxytryptophan Chemical compound C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 7
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 6
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 4
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229940054051 antipsychotic indole derivative Drugs 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 210000003568 synaptosome Anatomy 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- BUNUQMSIKUGVKD-UHFFFAOYSA-N 2-(1-phenylmethoxycarbonylpiperidin-4-yl)acetic acid Chemical compound C1CC(CC(=O)O)CCN1C(=O)OCC1=CC=CC=C1 BUNUQMSIKUGVKD-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000013275 serotonin uptake Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- XFGQLEIFBBNCOQ-UHFFFAOYSA-N 1-(1-benzylindol-3-yl)-2-piperidin-4-ylethanone Chemical compound N1CCC(CC1)CC(=O)C1=CN(C2=CC=CC=C12)CC1=CC=CC=C1 XFGQLEIFBBNCOQ-UHFFFAOYSA-N 0.000 description 1
- XFFQAOCOAJOAQG-UHFFFAOYSA-N 1-(1-methylindol-3-yl)-2-piperidin-4-ylethanone Chemical compound C12=CC=CC=C2N(C)C=C1C(=O)CC1CCNCC1 XFFQAOCOAJOAQG-UHFFFAOYSA-N 0.000 description 1
- YHQBFDOHJITHIC-UHFFFAOYSA-N 1-(5-methoxy-1h-indol-3-yl)-2-piperidin-4-ylethanone Chemical compound C12=CC(OC)=CC=C2NC=C1C(=O)CC1CCNCC1 YHQBFDOHJITHIC-UHFFFAOYSA-N 0.000 description 1
- URTPNQRAHXRPMP-UHFFFAOYSA-N 1-phenylmethoxycarbonylpiperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)OCC1=CC=CC=C1 URTPNQRAHXRPMP-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- VXZBYIWNGKSFOJ-UHFFFAOYSA-N 2-[4-[5-(2,3-dihydro-1H-inden-2-ylamino)pyrazin-2-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC=1N=CC(=NC=1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 VXZBYIWNGKSFOJ-UHFFFAOYSA-N 0.000 description 1
- HKYWCJOLDLYIOL-UHFFFAOYSA-N 3-(piperidin-4-ylmethyl)-1h-indole Chemical compound C=1NC2=CC=CC=C2C=1CC1CCNCC1 HKYWCJOLDLYIOL-UHFFFAOYSA-N 0.000 description 1
- MYTGFBZJLDLWQG-UHFFFAOYSA-N 5-chloro-1h-indole Chemical compound ClC1=CC=C2NC=CC2=C1 MYTGFBZJLDLWQG-UHFFFAOYSA-N 0.000 description 1
- DWAQDRSOVMLGRQ-UHFFFAOYSA-N 5-methoxyindole Chemical compound COC1=CC=C2NC=CC2=C1 DWAQDRSOVMLGRQ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000005055 alkyl alkoxy group Chemical group 0.000 description 1
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000012435 aralkylating agent Substances 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- TUSDRZPLYBKGLJ-UHFFFAOYSA-N bis(1-methoxyethoxy)alumane Chemical compound COC(C)O[AlH]OC(C)OC TUSDRZPLYBKGLJ-UHFFFAOYSA-N 0.000 description 1
- RQGVYBDLFLJWSA-UHFFFAOYSA-N bis[3-(1H-indol-2-yl)piperidin-4-yl]methanone Chemical compound N1C(=CC2=CC=CC=C12)C1CNCCC1C(=O)C1C(CNCC1)C=1NC2=CC=CC=C2C1 RQGVYBDLFLJWSA-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000006355 carbonyl methylene group Chemical group [H]C([H])([*:2])C([*:1])=O 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VXWPONVCMVLXBW-UHFFFAOYSA-M magnesium;carbanide;iodide Chemical compound [CH3-].[Mg+2].[I-] VXWPONVCMVLXBW-UHFFFAOYSA-M 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010517 secondary reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000723 toxicological property Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D227/00—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00
- C07D227/02—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D227/04—Heterocyclic compounds containing rings having one nitrogen atom as the only ring hetero atom, according to more than one of groups C07D203/00 - C07D225/00 with only hydrogen or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Description
Terapeutisk aktive indolderivater.
Oppfinnelsen angår nye indolderivater og medikamenter som inneholder disse, særlig for behandling av patologiske tilstander som skyldes forstyrrelse av de serotoninergiske sys-temer. Spesielt kan forbindelsene anvendes som psykotrope medikamenter, og da forst og fremst som antidepressive midler.
De aktuelle indolderivater har formelen:
hvor R betegner et hydrogenatom, en alkylgruppe med 1 - 4 C-atomer eller en aralkylgruppe hvor alkyldelen har 1 eller C-atomer, X betegner et hydrogenatom, en alkylgruppe, alkoksy-eller alkyltiogruppe som hver kan inneholde 1 - 4 C-atomer, eller betegner et halogenatom som klor, fluor, brom, eller en trifluormetyl-, nitro-, hydroksy- eller aminogruppe hvilke eventuelt er substituert med 1 eller to alkylgrupper, en acyl-eller alkylsulfonylgruppe, og A betegner gruppen -CO- eller
-C^-, og n har verdien Q, 1 eller 2.
Noen forbindelser med formel (i) er allerede kjent (J.I. de Graw, J. Heterocyclic Chemistry 1966, 3 (l), side 67 - 69, fransk patent 1693 M, engelsk patent 1126245). Noen forbindelser har vært anvendt som mellomprodukter for fremstilling av derivater med smertestillende virkning, men ingen av de aktuelle forbindelser har vært beskrevet hittil som medi-
kamenter.
Forbindelser med generell formel (i) hvor A betegner gruppen CH2kan fremstilles ved reduksjon av tilsvarende forbindelser med formel (I) hvori A danner gruppen CO.
Som reduksjonsmiddel kan man benytte hydrazin i nærvær av et alkalimetallhydroksyd som natriumhydroksyd eller et metallhydrid som natriumborhydrid, kalium-, litium-, litium-aluminium-, eller forskjellige komplekse hydrider som natrium-hydrid og bis(metoksy-2-etoksy)aluminium eller også diboran.
Forbindelser med generell formel (i) hvor A betegner gruppen CO og R betegner et hydrogenatom kan jtemstilles i to trinn i henhold til fblgende skjema:
Trinn å
En Grignard-reagens med formel (II) hvor X betegner et halogenatom fremstilles ved omsetning av det tilsvarende indol med et alkylmagnesium-halogenid som metylmagnesiumjodid i eter som f.eks. dietyleter, vanligvis ved opplosningsmidiets kokepunkt. Til den således fremstilte og avkjolte opplosning, mellom 0 og 20°C, tilsettes en opplosning i f.eks. benzen som inert opplosningsmiddel, av et syreklorid med formel (III)
hvor B betegner en amino-beskyttelsesgruppe for piperidinamin-et som f.eks. slike beskyttelsesgrupper som beskrives av R.A. Boissonnas i Advances in Organic Chemistry 3, side 159, Interscience (1963), f.eks. en benzyloksykarbonylgruppe.
Trinn b
Eliminering av beskyttelsesgruppen B kan skje på flere måter alt etter arten av B (se ovenfor). Spesielt kan avspalting av benzyloksykarbonylgrupper skje med syrer i et inert opplosningsmiddel som eddiksyre eller etanol, eller ved katalytisk hydrogenering eller med natrium i flytende ammoniakk.
Produkter med generell formel (i) hvor A betegner gruppen CO og R betegner en alkyl- eller aralkylgruppe kan fremstilles ved alkylering eller aralkylering av forbindelser med formel (IK), substituerte N-derivater (IV) som fremstilles på denne måten gjennomgår deretter de reaksjoner som beskrives over for fjerning av beskyttelsesgruppen B.
For alkylering eller aralkylering av forbindelser med formel (IV) benyttes kjente metoder for N-substituering av indolringen, som f.eks. beskrevet av W.J. Houlihan, Indoles-part I, side 90, Wiley - Interscience (1972). For å unngå sekundærreaksjoner på karbonylgruppen i molekylet er det en fordel å unngå for kraftige metalliseringsreagenser som hydrider eller amider av alkalimetaller. Med fordel benyttes alkyleringsmidler eller aralkyleringsmidler av vanlig type som alkyl- eller aralkylhalogenider og fortrinnsvis i nærvær av en baseakseptor som kaliumkarbonat, i et inert opplosningsmiddel som aceton.
De fremstilte forbindelser kan renses fysisk (destil-lasjon, krystallisasjon, kromatografering o.-l.) eller kjemisk (saltdannelse og regenerering av basen, og lignende metoder). De fremstilte forbindelser kan omdannes til salter ved tilset-ning av mineralske eller organiske syrer i egnet opplosningsmiddel.
De folgende eksempler skal på ikke-begrensede måte illustrere fremstilling av forbindelser i henhold til oppfinnelsen.
Eksempel 1 - 3- indolvl-( 4-- prperidy lmetyl)- keton
En suspensjon av 7,1 g magnesiumspon i 90 ml vannfri eter tilsettes en jodkrystall. Man oppvarmer til tilbakelbp og tilsetter langsomt en opplosning av 42 g metyljodid i 90
ml vannfri eter. Tilbakelbpskoking opprettholdes til magne-siumet er forsvunnet. Til den avkjolte opplosning (20°C) tilsettes i lbpet av 10 minutter 15,7 g indolopplosning i 90 ml vannfri eter. Den eksoterme reaksjon bringer eteren til å koke og man fortsetter kokingen i 1 time. Til den fremstilte opplosning, avkjblt til mellom 0 og 5°C, settes litt etter litt en benzenopplbsning av l-benzyloksylkarbonyl-4-piperidyl-eddiksyreklorid (fremstilt ved omsetning av 31,8 g tionylklo-rid og 37,1 g l-benzyloksykarbonyl-4-piperidyl-eddiksyre, i henhold til I. De Graw i J. Hetero-chem. 3, 90, (1966). Det dannes en olje som derpå krystalliserer. Suspensjonen rbres ved romtemperatur i 15 timer. Man tilsetter 30 ml vandig
2-N saltsyre. Produktet opploses umiddelbart.
Den organiske fase dekanteres fra, torkes over mag-nesiumsulfat og inndampes. Restoljen (54,3 g) opploses i 500 ml 5-N saltsyre i etanol. Den fremstilte opplosning kokes ved tilbakelbp i 2 timer og inndampes under nedsatt trykk. Inn-dampningsresten opploses i 200 ml kokende isopropanol og opp-løsningen kjoles til 0°C. Krystallene oppsamles, "torkes og omkrystailiseres fra metanol. Man får 20 g 3-indolyl-(4-piperi-dylmetyl)-keton-hydroklorid som smelter over 280°C.
Analyse, for C15H18<N>20.H<31
På lignende måte fremstilles de folgende forbindelser: Eksempel 2 -( 5- metoksy- 3- indolvl)( 4- piperidylmetyl)- keton
Ut fra 5-metoksyindol og l-benzyloksykarbonyl-4-piperidyl-eddiksyre fremstilles hydrokloridet av 5-metoksy-3-indolyl(4-piperidylmetyl)-keton som smelter ved 265°C.
Analyse for C-^H^I^O^HCl
Eksempel 3 - 5- klor- 3- indolyl-( 4-" piperidyl- metyl)- keton
Ut fra 5-klorindol og l-benzyloksykarbonyl-4-piperidyl-eddiksyre fremstilles hydrokloridet av 5-klor-3-indolyl-(4-piperidylmetyl)-keton som smelter ved over 260°C.
Analyse for C15H17C1N20.HC1
Eksempel 4 - l-( 3~ indolyl)- 3( 4- piperidyl)- propanon
Ut fra indol og l-benzyloksykarbonyl-4-piperidyl-propionsyre får man 3-indolyl-3-(4-piperidyl)-propanon-metan-sulfonat, smeltepunkt 198°C.
Analyse for Cl6H2G)N20. CH^SO^
Eksempel 5: 3- indolyl- 4- piperidyl- ket5n~
Ut fra indol og l-benzyoloksykarbonyl-4-piperidyl-karboksylsyre får man 3-indolyl-4-piperidyl-keton-hydroklorid som smelter ved 260°C.
Analyse for C-,-H-, fiN?0. HC1
Eksempel 6 -( l- metyl- 3- indolyl)( 4- piperidylmetyl)- keton
Man koker ved tilbakelop i 6 timer en suspensjon av 2 g vannfri kaliumkarbonat i en opplosning av 0,6 g 3-indolyl-(l-benzyloksykarbonyl-4-piperidylmetyl)-keton og 1 g metyljodid. Etter avkjoling ved romtemperatur frafiltreres kalium-karbonatet og filtratet inndampes under nedsatt trykk. Den oljeaktige rest opploses i 5 ml 5-N saltsyre i etanol og opp-løsningen holdes ved tilbakelop 1 time.. Etanolen avdampes i vakuum og residuet krystalliseres i etanol. Man får 0,28 g (l-metyl-3-indolyl)(4-piperidylmetyl)-keton-hydroklorid som smelter ved 272°C.
NMR-spektrum: (CDCl^- CF^COOH) S : 8,2 - 7,3 ppm (arom.) 3,6 - 2,8 ppm (-NCH2- og - C0-CH2). 3,8 ppm (N - CH^) - 1,6 - 2,2 ppm (CH og CH2).
På lignende måte fremstilles folgende forbindelse:
Eksempel 7: ( l- benzvl- 3- indolvl) ( 4- prperi dy lmetyl) - keton
Ut fra 3-indolyl-(l-benzyloksykarbonyl-4-piperidyl)-keton og benzylbromid fremstilles (l-benzyl-3-indolyl)(4-piper-idylmetyl)-keton-hydroklorid som smelter ved 152°C.
NMR-spektrum: (CDCl^- CF^COOH) <f : 8,2 - 7,3 (arom.) 7,6 ppm (NH). 5,4 ppm (-CH2- C6H5_). 3,6 3 ppm (N - CH2og C0CH2) - 1,7 - 2,2 ppm (CH - og CH2).
Eksempel 8 - 4/ 2-( 5- metoksv- 3- indolyl)- etyl7- piperldin
Under nitrogenatmosfære settes en suspensjon av 0,152 g aluminium-litium-hydrid i 8 ml tetrahydrofuran, en opplosning av 0,54 g (5-metoksy-3-indolyl) (4-piperidylmetyl).-keton i 4 ml tetrahydrofuran. Man oppvarmer ved tilbakelop i 4 timer og avkjoler til 0°C og tilsetter fortlopende 0,15 nil vann, 0,12 ml vandig natriumhydroksydopplbsning 5-N og 0,6 ml vann. De dannede mineralsalter filtreres fra og man vasker to ganger med 20 ml metylenklorid ialt.
De organiske opplesninger som dannes samles og torkes over kaMumkarbonat og inndampes under nedsatt trykk. Man får 0,3 g olje som krystalliseres fra etylacetat. Man får titbel-forbindelsen 4/2-(5-metoksy-3-indolyl)-etyl7-piperidin som smelter ved 114°C.
NMR-spektrum (CDCl^) cf : 6,8 - 7,2 ppm (aroma.)
3*8 ppm (CH30). 2,3 ppm (N - CH2, - j- "CH^;1-2 ppm (CH og CH2);Eksempel 9 - 4-/. 2-( l- metvl- 3- indolyl)- etyl7- pi" peridin;Til en opplosning av 0,29 g (l-metyl-3-indolyl)-(4-piperidyl-metyl)-keton i 10 ml toluen settes 0,5 g bis-(2-metoksyetoksy)-natrium-aluminium-hydrid som 70% opplosning i toluen.. Blandingen oppvarmes ved tilbakelbp i 15 timer og avkjbles til 0°!K. Man tilsetter dråpevis 10 ml vandig 5-N natriumhydroksyd og rbrer i 1 time. Den organiske fasen dekanteres fra, vaskes med vann, torkes på kaliumkarbonat og avdampes under nedsatt trykk. Man får 0,26 g olje som renses ved kromatografi og ved saltdannelse til hydroklorid. Man får 0,1 g hydroklorid av 4-/2^(l-metyl-3-indolyl)-etyl7-piperidin med smeltepunkt 198°C. ;Analyse for C-^H^N^HCl; ;
På lignende måte fremstilles de folgende forbindelser: ;Eksempel 10 - 4-/ 2-( 3- indolvl)- etyl7- piperidin;Ved reduksjon av 3-indolyl-(4-piperidinmetyl)-keton får man 4-/2-(3-indolyl)-etyl7-piperidin hvis hydroklorid smelter ved 167°C. ;Analyse for C15H20N2.HC1; ;
Eksempel 11: 4- fendolylmetyl)- piperidin;Ved reduksjon av 3-indolyl-4-piperidyl-keton får man ;4-(3-indolymetyl)-piperidin som smelter ved 172°C. ;Analyse for C]_4hiqn2; ;
Eksempel 12: 4-^ 2-( 5- klor- 3- indolyl)- etyl7- piperidin ;Ved reduksjon av 5-klor-3-indolyl-(4-piperidyl-metyl)-keton får man tittelforbindelsen som smelter ved 160°C. ;Analyse for C-^H-^CII^; ;
Eksempel 13 - 4-/ 5- ( 3- indoly]) propvl7- piperidin;Ved reduksjon av 1-(3-indolyl)-3(4-piperidyl)-propanon får man tittelforbindelsen som en olje hvis fumarsyre-salt smelter ved 228°C. ;Anhydrotitrimetrisk dose: 100%;NMR-spektrum (CDC1 ): = 7,5 - 7 - 6,7 (arom.);2,4 - 3,1. (N - C<H>2; CH2),1-2 ppm (CH;og CH2);Eksempel 14: 4-/ 2-( l- benzyl- 3- indolvl)- etvl7- piperidin;Ved reduksjon av (l-benzyl-3-indolyl)-(4-piperidyl-metyl)-keton får man 4-/2-(l-benzyl-3-indolyl)-etyl7-piperidin som en ikke-krystalliserbar olje. ;NMR-spektrum (CDCl^- CF3 COOH) $ : 5,2 ppm (CH2- C6H5) 8,2 - 7,3 ppm (arom.) 3-3,6 ppm ( N - CH2) 1,7 - 2,2 ppm (CH og CH2) ;Farmakologiske egenskaper;Den farmakologiske virkning til forbindelser i henhold til oppfinnelsen er påvist med en inhiberingsprbve på gjenopptak av monoaminer i hjernen, in vitro, ved synaptosomer på hjernerotte, i henhold til- metoden beskrevet av Kannengiesser og medarbeidere (Biochem. Pharmacol. 22, 73, 1973). ;Resultatene som fremgår av tabellen viser at forbindelser ifblge oppfinnelsen har den spesielle evne at de virker selektivt på hjerne-serotonien, idet virkningene overfor andre overfbringsforbindelser (noradrenalin og dopamin) er 20 - 3000 ganger svakere. Særlig har forbindelser ifblge eksempel 1, ;9, 10 og 13 en mer selektiv virkning enn clomipramih.;ID^q for gjenopptak av synaptosomer i hjerne -;rotte av noradrenalin (NA), dopamin (DA) og serotonin (5HT) ; ;
ID^q er lik dose som gir 50 % inhibering.;Virkningen av forbindelser i henhold til oppfinnelsen med hensyn på blokkering ar gjenopptak av seretonin på-vises også ved potensialiseringsforsok med 5-hydroksy-tryptofan (5-HTP).;Forbindelser ifblge oppfinnelsen har den inter-essante egenskap å forsterke eller potensialisere virkningen av 5-HTP soiib er forlbper for serotonin. Denne egenskap er påvist hos hannmus CD^(Charles River), med en metode beskrevet av Buus Lassens J. (Acta Pharmacol, 31, suppleringsbind 1, 11 - 1972). Forsbket består i å finne forsterkningen-av hypermobiliteten som induseres av 5-HTP. I hby dose gir denne forlbper en hypermobilitet uten sprang som er meget karakter-istisk. Inhibitorer for serotonin-opptak eristand til å frem-kalle samme fenomen hos mus som er forhåndbehandlet med en lav inaktiv dose av 5-HTP. ;Mus i grupper på 25 behandles med 150 mg/kg i.p.;av 5-HTP. Forsbksforbindelsene gis subkutant, 30 minutter etter 5-HTP og en kontrollgruppe mottar bare opplbsnings-væsken. Dyrenes hyper-bevegelighet måles hvert 45de til 75de minutt etter administrasjon ar 5-HTP. Resultatene innen gruppen uttrykkes som prosent b<*>kning av mobiliteten i forhold til kontrollgruppen.
Tabellen nedenfor angir tall som er målt for tre forbindelser.
Aktiviteten stemte godt overens med de kraftige inhiberende virkninger for serotoninopptak som obseres in. vitro ved rotte-synaptosomer.
Toksikologiske egenskaper
Toksisitet og maksimal-symptomer for forbindelser ifblge oppfinnelsen er målt på hannmus CD-j_ (Charles River), ved intravenbs og oral admini strås jon. LD5q er beregnet etter tre timers observasjon i henhold til den kummulative metoden til J.J. Reed og H Muench (Am. J. Hyg., 27, 493, 1938).
LDcjq -verdiene er oppsatt i nedenstående tabell:
Forbindelsene oppforer seg altså som relativt lite giftige stoffer hos mus.
Terapeutisk anvendelse.
Forbindelsene ifolge oppfinnelsen og deres farmasøy-tiske salter kan brukes i medisinen som tabletter, kapsler, suppositorier, oppløsninger, dryppinfusjoner, injeksjoner etc. for behandling av patologiske tilstander som skyldes forstyrrel-ser av det serotoninergiske system, særlig forskjellige.psyk-iske vanskeligheter med depressiv karakter.
Den anvendte dose vil avhenge av den bnskede virkning og administråsjonsveien. Oral kan dosen f.eksæ ligge mellom 5 og 250 .mg aktivt stoff pr. dag, i enhetsdoser på 1-- 50 mg.
Claims (1)
- Nye medikamenter, særlig for behandling av patologiske tilstander som skyldes forstyrrelse av det serotoninergiske system, karakterisert ved et innhold av en forbindelse med generell formelhvor R betegner et hydrogenatom, en alkylgruppe med 1-4 C-atomer eller en aralkylgruppe hvor alkyldelen har 1 eller 2 C-atomer, X betegner et hydrogenatom, en alkyl-, alkoksy-eller alkyltiogruppe som hver kan inneholde 1-4 C-atomer, eller betegner et halogenatom, en:trifluormetyl-, nitro-, hydroksy- eller aminogruppe som eventuelt er substituert med en eller to alkylgrupper, eller med en acyl- eller alkylsulfonylgruppe, A betegner gruppen -CO- eller -CH^ - og n kan betegne 0, 1 eller 2.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR7538051A FR2334358A1 (fr) | 1975-12-12 | 1975-12-12 | Nouveaux medicaments derives de l'indole |
Publications (1)
Publication Number | Publication Date |
---|---|
NO761407L true NO761407L (no) | 1977-06-14 |
Family
ID=9163660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO761407A NO761407L (no) | 1975-12-12 | 1976-04-23 |
Country Status (23)
Country | Link |
---|---|
US (1) | US4064255A (no) |
JP (1) | JPS5272829A (no) |
AR (1) | AR212515A1 (no) |
AT (1) | AT354447B (no) |
AU (1) | AU508906B2 (no) |
BE (1) | BE847283A (no) |
CA (1) | CA1088939A (no) |
CH (1) | CH620436A5 (no) |
DE (1) | DE2618152C2 (no) |
DK (1) | DK190276A (no) |
ES (1) | ES454162A1 (no) |
FR (1) | FR2334358A1 (no) |
GB (1) | GB1561111A (no) |
GR (1) | GR58260B (no) |
HU (1) | HU175629B (no) |
IL (1) | IL50881A (no) |
IT (1) | IT1125233B (no) |
LU (1) | LU76372A1 (no) |
MX (1) | MX4253E (no) |
NL (1) | NL179975C (no) |
NO (1) | NO761407L (no) |
PT (1) | PT65950B (no) |
ZA (1) | ZA767340B (no) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4208417A (en) * | 1978-06-29 | 1980-06-17 | Pharmindustrie | Indole derivatives and their use as anxiolytics |
FR2430769A1 (fr) * | 1978-07-13 | 1980-02-08 | Pharmindustrie | Nouvelle composition analgesique contenant de l'((indolyl-3)-2 ethyl)-4 piperidine |
ZW19381A1 (en) * | 1980-08-12 | 1983-03-09 | Glaxo Group Ltd | Heterocyclic compounds |
DE3035403C2 (de) | 1980-09-19 | 1982-08-26 | Rütgerswerke AG, 6000 Frankfurt | Verfahren zur Herstellung von 5-Chlorindol |
FR2506309A1 (fr) * | 1981-05-22 | 1982-11-26 | Pharmindustrie | ((tetra- et hexahydro pyridyl-4)-2 ethyl)-3 indoles et leur utilisation comme medicaments |
FR2506310A1 (fr) | 1981-05-22 | 1982-11-26 | Pharmindustrie | ((alkyl- et alcenyl-3 piperidyl-4)-2 ethyl)-3 indoles et leur utilisation comme medicaments |
US4803218A (en) * | 1982-09-29 | 1989-02-07 | Mcneilab, Inc. | 3-aminoalkyl-1H-indole-5-urea and amide derivatives |
JPS6084281A (ja) * | 1983-09-14 | 1985-05-13 | Yoshitomi Pharmaceut Ind Ltd | 3−インド−ルカルボキサミド類 |
JPS60142981A (ja) * | 1983-12-28 | 1985-07-29 | Yoshitomi Pharmaceut Ind Ltd | 3−インド−ルカルボキサミド誘導体 |
US4548939A (en) * | 1984-10-01 | 1985-10-22 | Janssen Pharmaceutica N. V. | 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones |
GB8600397D0 (en) * | 1986-01-08 | 1986-02-12 | Glaxo Group Ltd | Chemical compounds |
TW197435B (no) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
WO1992019595A1 (en) * | 1991-05-07 | 1992-11-12 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
TW263504B (no) * | 1991-10-03 | 1995-11-21 | Pfizer | |
US5462934A (en) * | 1992-03-09 | 1995-10-31 | Takeda Chemical Industries | Condensed heterocyclic ketone derivatives and their use |
CA2092112A1 (en) * | 1992-03-23 | 1993-09-24 | Nobuyoshi Iwata | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use |
US5358956A (en) * | 1992-10-14 | 1994-10-25 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5340798A (en) * | 1992-10-14 | 1994-08-23 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
DE69327536T2 (de) * | 1992-10-14 | 2000-07-06 | Merck & Co., Inc. | Fibrinogenrezeptor-antagonisten |
US5786373A (en) * | 1992-10-14 | 1998-07-28 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5648368A (en) * | 1992-12-01 | 1997-07-15 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5334596A (en) * | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
GB9310582D0 (en) * | 1993-05-22 | 1993-07-07 | Smithkline Beecham Plc | Pharmaceuticals |
US5397791A (en) * | 1993-08-09 | 1995-03-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5789421A (en) * | 1995-10-26 | 1998-08-04 | Merck & Co., Inc. | Fibrinogen receptor antagonist |
US5780480A (en) * | 1996-02-28 | 1998-07-14 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
US5889023A (en) * | 1996-05-10 | 1999-03-30 | Merck & Co., Inc. | Fibrinogen receptor antagonist |
CN1163224C (zh) | 1998-09-30 | 2004-08-25 | 武田药品工业株式会社 | 改善膀胱排泄能力的药物 |
WO2005060968A1 (en) | 2003-12-11 | 2005-07-07 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
WO2005092885A1 (en) * | 2004-02-27 | 2005-10-06 | Eli Lilly And Company | 4-amino-piperidine derivatives as monoamine uptake inhibitors |
US20080261955A1 (en) * | 2004-10-01 | 2008-10-23 | Timothy Dinan | Use of Pharmaceutical Compositions of Lofepramine for the Treatment of Adhd, Cfs, Fm and Depression |
JP3816093B1 (ja) * | 2005-10-03 | 2006-08-30 | マイルストーン株式会社 | 撮像レンズ |
EP1842541A1 (en) * | 2006-03-29 | 2007-10-10 | G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg | Plant components and extracts and uses thereof |
WO2014125084A1 (en) | 2013-02-14 | 2014-08-21 | Technische Universität München | Hydroxyindalpine derivatives and their medical use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136770A (en) * | 1960-04-01 | 1964-06-09 | Neisler Lab Inc | Indolyl substituted piperidines |
GB925429A (en) * | 1960-04-01 | 1963-05-08 | Irwin Neisler & Co | Indole derivatives |
US3471499A (en) | 1965-12-03 | 1969-10-07 | American Home Prod | 1,4-bis-(2-indol-3-yl-ethyl)piperazines |
GB1237008A (en) * | 1968-12-18 | 1971-06-30 | Pfizer Ltd | Novel indoline derivatives |
GB1436771A (en) * | 1973-02-16 | 1976-05-26 | Labaz | Indole derivatives and process for preparing the same |
-
1975
- 1975-12-12 FR FR7538051A patent/FR2334358A1/fr active Granted
-
1976
- 1976-04-13 NL NLAANVRAGE7603881,A patent/NL179975C/xx not_active IP Right Cessation
- 1976-04-23 NO NO761407A patent/NO761407L/no unknown
- 1976-04-26 DE DE2618152A patent/DE2618152C2/de not_active Expired
- 1976-04-26 US US05/679,970 patent/US4064255A/en not_active Expired - Lifetime
- 1976-04-28 DK DK190276A patent/DK190276A/da unknown
- 1976-05-26 GB GB21778/76A patent/GB1561111A/en not_active Expired
- 1976-10-14 BE BE171515A patent/BE847283A/xx not_active IP Right Cessation
- 1976-11-10 IL IL50881A patent/IL50881A/xx unknown
- 1976-11-29 MX MX76100516U patent/MX4253E/es unknown
- 1976-12-08 GR GR52353A patent/GR58260B/el unknown
- 1976-12-08 CH CH1545176A patent/CH620436A5/fr not_active IP Right Cessation
- 1976-12-09 JP JP51148256A patent/JPS5272829A/ja active Granted
- 1976-12-09 AU AU20423/76A patent/AU508906B2/en not_active Expired
- 1976-12-09 AT AT910276A patent/AT354447B/de not_active IP Right Cessation
- 1976-12-09 ZA ZA00767340A patent/ZA767340B/xx unknown
- 1976-12-10 ES ES454162A patent/ES454162A1/es not_active Expired
- 1976-12-10 HU HU76MA2838A patent/HU175629B/hu unknown
- 1976-12-10 LU LU76372A patent/LU76372A1/xx unknown
- 1976-12-10 PT PT65950A patent/PT65950B/pt unknown
- 1976-12-10 CA CA267,635A patent/CA1088939A/fr not_active Expired
- 1976-12-10 AR AR265798A patent/AR212515A1/es active
- 1976-12-10 IT IT69941/76A patent/IT1125233B/it active
Also Published As
Publication number | Publication date |
---|---|
IL50881A (en) | 1979-11-30 |
CA1088939A (fr) | 1980-11-04 |
US4064255A (en) | 1977-12-20 |
DK190276A (da) | 1977-06-13 |
IL50881A0 (en) | 1977-01-31 |
JPS5272829A (en) | 1977-06-17 |
AU508906B2 (en) | 1980-04-03 |
NL179975B (nl) | 1986-07-16 |
BE847283A (fr) | 1977-04-14 |
AT354447B (de) | 1979-01-10 |
CH620436A5 (no) | 1980-11-28 |
ATA910276A (de) | 1979-06-15 |
GB1561111A (en) | 1980-02-13 |
DE2618152C2 (de) | 1983-05-05 |
FR2334358B1 (no) | 1979-06-29 |
JPS56435B2 (no) | 1981-01-08 |
ZA767340B (en) | 1978-01-25 |
MX4253E (es) | 1982-03-04 |
AR212515A1 (es) | 1978-07-31 |
ES454162A1 (es) | 1978-02-16 |
FR2334358A1 (fr) | 1977-07-08 |
AU2042376A (en) | 1978-06-15 |
DE2618152A1 (de) | 1977-06-16 |
HU175629B (hu) | 1980-09-28 |
LU76372A1 (no) | 1978-07-10 |
GR58260B (en) | 1977-09-15 |
PT65950B (fr) | 1978-06-15 |
NL179975C (nl) | 1986-12-16 |
IT1125233B (it) | 1986-05-14 |
PT65950A (fr) | 1977-01-01 |
NL7603881A (nl) | 1977-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO761407L (no) | ||
FI81567C (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara n-substituerade 4-oxipiperidinfoereningar. | |
US5071859A (en) | N-substituted azaheterocyclic carboxylic acids and pharmaceutical uses | |
US3080372A (en) | 1-aroylalkyl-4-arylpiperidine derivatives | |
US4711899A (en) | 2-(4-benzoyl-1-piperidyl)-1-phenylalkanol derivatives | |
DK153397B (da) | Analogifremgangsmaade til fremstilling af 1,3,4-trisubstituerede 4-arylpiperidiner eller farmaceutisk acceptable syreadditionssalte deraf | |
NO122814B (no) | ||
Vecchietti et al. | (1S)-1-(Aminomethyl)-2-(arylacetyl)-1, 2, 3, 4-tetrahydroisoquinoline and heterocycle-condensed tetrahydropyridine derivatives: members of a novel class of very potent. kappa. opioid analgesics | |
DK162629B (da) | 2-substituerede 1-aralkyl-imidazoler og farmaceutiske midler der indeholder disse, anvendelse heraf til fremstilling af farmaceutiske midler samt fremgangsmaade til fremstilling heraf | |
CA2110574A1 (en) | Tryptamine analogues, their synthesis and their use as 5-ht1-like or 5-ht2 receptor agonists | |
NO851393L (no) | Fremgangsmaate for fremstilling av n-aryl-n-(4-piperidinyl)amider. | |
NO760993L (no) | ||
US4110459A (en) | Benzoylpiperidylalkylindoles in alleviating pain | |
Ginos et al. | Cholinergic effects of molecular segments of apomorphine and dopaminergic effects of N, N-dialkylated dopamines | |
DK155793B (da) | Analogifremgangsmaade til fremstilling af 3-substituerede pyrrolidiner eller piperidiner samt 3-substituerede pyrrolidiner eller piperidiner til brug som udgangsmateriale ved fremgangsmaaden | |
NO803453L (no) | Fremgangsmaate ved fremstilling av piperidylbenzimidazolonderivater | |
NO155137B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive derivater av 2-(4-piperidyl)-1-(4-kinolyl)-etanon. | |
PT100860A (pt) | Novos derivados de beta-carbolionas, processo para a sua preparacao e composicoes farmaceuticas que as contem | |
US3518270A (en) | 6,7,12,13 - tetrahydro - 6,12 - imino - 5h - benzo(5,6)cyclooct(1,2 - b)indole derivatives and process for their production | |
JPS6356223B2 (no) | ||
Šafář et al. | Combined Chemical, Biological and Theoretical DFT‐QTAIM Study of Potent Glycosidase Inhibitors Based on Quaternary Indolizinium Salts | |
NO762085L (no) | ||
CA1243033A (en) | Process for preparing 4-¬2- (dialkylamino)ethyl|isatins | |
NO821700L (no) | 3-(2-(3-alkyl og alkenyl-4-piperidyl)-etyl)-indoler. | |
PL71070B1 (no) |